Literature DB >> 32604408

Clinical trials of broadly neutralizing monoclonal antibodies for HIV Prevention: A Review.

Sharana Mahomed1, Nigel Garrett1,2, Cheryl Baxter1, Quarraisha Abdool Karim1,3, Salim S Abdool Karim1,3.   

Abstract

Passive immunisation with broadly neutralizing antibodies (bnAbs) is a promising approach to reduce the 1.7 million annual HIV infections globally. Early studies on bnAbs showed safety in humans, but short elimination half-lives and low potency and breadth. Since 2010, several new highly potent bnAbs have been assessed in clinical trials alone or in combination for HIV prevention. Published data indicate that these bnAbs are safe and have a half-life ranging from 15 to 71 days. Only intravenous VRC01 has advanced to an efficacy trial, with results expected in late 2020. If bnAbs are shown to be effective in preventing HIV infection, they could fast-track vaccine development as correlates of protection, and contribute as passive immunisation to achieving the goal of epidemic control. The purpose of this review is to describe the current status and provide a synopsis of the available data on bnAbs in clinical trials for HIV prevention.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; Monoclonal antibodies; broadly neutralising antibodies; clinical trials

Year:  2020        PMID： 32604408     DOI： 10.1093/infdis/jiaa377

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

Authors:  William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

2.  Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.

Authors:  Qingbo Liu; Peng Zhang; Huiyi Miao; Yin Lin; Young Do Kwon; Peter D Kwong; Zahra Rikhtegaran-Tehrani; Michael S Seaman; Anthony L DeVico; Mohammad M Sajadi; Paolo Lusso
Journal:  J Virol       Date:  2021-05-24       Impact factor: 5.103

3.  Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.

Authors:  Amit Kumar; Elena E Giorgi; Joshua J Tu; David R Martinez; Joshua Eudailey; Michael Mengual; Manukumar Honnayakanahalli Marichannegowda; Russell Van Dyke; Feng Gao; Sallie R Permar
Journal:  PLoS Pathog       Date:  2021-04-02       Impact factor: 7.464

4.  HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.

Authors:  Brian Moldt; Abishek Chandrashekar; Erica N Borducchi; Joseph P Nkolola; Heather Stephenson; Mark Nagel; Magdeleine Hung; Joshua Goldsmith; Craig S Pace; Brian Carr; Nathan D Thomsen; Wade S Blair; Romas Geleziunas; Dan H Barouch
Journal:  PLoS Pathog       Date:  2022-04-22       Impact factor: 7.464

5.  Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.

Authors:  Hugh C Welles; Hannah A D King; Leonard Nettey; Nicole Cavett; Jason Gorman; Tongqing Zhou; Yaroslav Tsybovsky; Renguang Du; Kaimei Song; Richard Nguyen; David Ambrozak; Amy Ransier; Chaim A Schramm; Nicole A Doria-Rose; Adrienne E Swanstrom; James A Hoxie; Celia LaBranche; David C Montefiori; Daniel C Douek; Peter D Kwong; John R Mascola; Mario Roederer; Rosemarie D Mason
Journal:  PLoS Pathog       Date:  2022-06-16       Impact factor: 7.464

6.  Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.

Authors:  Sharana Mahomed; Nigel Garrett; Edmund V Capparelli; Farzana Osman; Ishana Harkoo; Nonhlanhla Yende-Zuma; Tanuja N Gengiah; Derseree Archary; Natasha Samsunder; Cheryl Baxter; Nonhlanhla N Mkhize; Tandile Modise; Kevin Carlton; Adrian McDermott; Penny L Moore; Quarraisha Abdool Karim; Dan H Barouch; Patricia E Fast; John R Mascola; Julie E Ledgerwood; Lynn Morris; Salim S Abdool Karim
Journal:  J Infect Dis       Date:  2022-08-26       Impact factor: 7.759

7.  Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.

Authors:  Sharana Mahomed; Nigel Garrett; Quarraisha A Karim; Nonhlanhla Y Zuma; Edmund Capparelli; Cheryl Baxter; Tanuja Gengiah; Derseree Archary; Natasha Samsunder; Nicole D Rose; Penny Moore; Carolyn Williamson; Dan H Barouch; Patricia E Fast; Bruno Pozzetto; Catherine Hankins; Kevin Carlton; Julie Ledgerwood; Lynn Morris; John Mascola; Salim Abdool Karim
Journal:  BMJ Open       Date:  2020-11-26       Impact factor: 2.692

8.  HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.

Authors:  Simone I Richardson; Frances Ayres; Nelia P Manamela; Brent Oosthuysen; Zanele Makhado; Bronwen E Lambson; Lynn Morris; Penny L Moore
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

9.  Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis.

Authors:  David A Spencer; Benjamin S Goldberg; Shilpi Pandey; Tracy Ordonez; Jérémy Dufloo; Philip Barnette; William F Sutton; Heidi Henderson; Rebecca Agnor; Lina Gao; Timothée Bruel; Olivier Schwartz; Nancy L Haigwood; Margaret E Ackerman; Ann J Hessell
Journal:  Nat Commun       Date:  2022-02-03       Impact factor: 17.694

10.  Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants.

Authors:  Catherine M Moore; Melanie Grandits; Clemens Grünwald-Gruber; Friedrich Altmann; Maria Kotouckova; Audrey Y-H Teh; Julian K-C Ma
Journal:  Retrovirology       Date:  2021-06-28       Impact factor: 4.602
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.